Just to clarify for anyone reading, the method licensed by NWBO from Roswell isn’t just about using dendritic cells with lysate. It’s specifically designed to activate T cells that can recognize not only tumor cells but also the blood vessels and support structures feeding the tumor. That vascular targeting effect, achieved through broad antigen exposure from pooled lysate, is a key part of what makes the platform unique.
Also worth noting, those Mayo trials were funded only by the Ivy Foundation and conducted through Mayo Clinic. No Merck, no NIH, no NCI, and no pharma involvement. That’s important. It kept the platform development independent, under the radar, and unencumbered by outside ownership. Ivy also later funded Dr. Liau’s DCVax work at UCLA. Looking back, it’s clear they were backing the method itself, not any one institution. Now that same method sits under NWBO’s exclusive license.
Bullish
Market Data 
Markets 
